Cu-doped mesoporous TiO2 photocatalyst for efficient degradation of organic dye via visible light photocatalysis.

A solvothermal method was used to synthesize the mesoporous TiO2, (1-3w %) Cu-doped mesoporous TiO2 membrane with the help of a bioreactor. To understand the physicochemical composition of all synthesized nanomaterials, the structure, morphology and crystallinity of the materials were studied using X-ray diffractometer (XRD), Field emission scanning electron microscopy (FESEM), Fourier transform-infrared (FTIR), Energy dispersive X-ray spectroscopy (EDS) and cyclic voltammetry (CV). Under artificial light source (500 W mercury bulb) irradiations, the nano catalysts' catalytic effectiveness was examined for the azo dyes, namely Congo red. Cu-doping causes a shift in the light absorption of mTiO2 from the ultraviolet to the visible region. The 3w% Cu-doped mTiO2 photocatalyst exhibits lower band gap energy (2.6eV) than TiO2 which is 3.2 eV to efficiently utilize solar energy. As a result, the light absorption was shifted towards the visible spectrum. The recommended mTiO2 and (1, 2, 3) w% Cu-doped mTiO2 photocatalysts were used to photodegrade Congo red and methylene blue. For the degradation of CR, the mTiO2 photocatalyst exhibited 61% and 3w% Cu-doped mTiO2 demonstrated 99% photocatalytic performance after 50 min. A variety of scavengers were also utilized to distinguish the active species by catching the radicals and holes created during the process of photocatalytic degradation. CV indicates the presence of Cu2+ and Cu1+ in Cu-doped mTiO2. Oxygen vacancies and the electronegative surface of Cu1+ seem to perform the photocatalytic reduction of CR.

Folate Conjugated Polyethylene Glycol Probe for Tumor-Targeted Drug Delivery of 5-Fluorouracil.

A targeted delivery system is primarily intended to carry a potent anticancer drug to specific tumor sites within the bodily tissues. In the present study, a carrier system has been designed using folic acid (FA), bis-amine polyethylene glycol (PEG), and an anticancer drug, 5-fluorouracil (5-FU). FA and PEG were joined via an amide bond, and the resulting FA-PEG-NH2 was coupled to 5-FU producing folate-polyethylene glycol conjugated 5-fluorouracil (FA-PEG-5-FU). Spectroscopic techniques (UV-Vis, 1HNMR, FTIR, and HPLC) were used for the characterization of products. Prodrug (FA-PEG-5-FU) was analyzed for drug release profile (in vitro) up to 10 days and compared to a standard anticancer drug (5-FU). Folate conjugate was also analyzed to study its folate receptors (FR) mediated transport and in vitro cytotoxicity assays using HeLa cancer cells/Vero cells, respectively, and antitumor activity in tumor-bearing mice models. Folate conjugate showed steady drug release patterns and improved uptake in the HeLa cancer cells than Vero cells. Folate conjugate treated mice group showed smaller tumor volumes; specifically after the 15th day post-treatment, tumor sizes were decreased significantly compared to the standard drug group (5-FU). Molecular docking findings demonstrated importance of Trp138, Trp140, and Lys136 in the stabilization of flexible loop flanking the active site. The folic acid conjugated probe has shown the potential of targeted drug delivery and sustained release of anticancer drug to tumor lesions with intact antitumor efficacy.